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Edited by Ned ManteiAbstract DNA polymerase (Pol ) is an error-prone repair
DNA polymerase that has been shown to create genetic
instability and tumorigenesis when overexpressed by only 2-fold
in cells, suggesting that a rigorous regulation of its expression
may be essential in vivo. To address this question, we have
generated mice which express a transgene (Tg) bearing the Pol
cDNA under the control of the ubiquitous promoter of the mouse
H-2K gene from the major histocompatibility complex. These
mice express the Tg only in thymus, an organ which normally
contains the most abundant endogenous Pol mRNA and protein,
supporting the idea of a tight regulation of Pol in vivo.
Furthermore, we found no tumor incidence, suggesting that the
single Pol overexpression event is not suﬃcient to initiate
tumorigenesis in vivo.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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There are numerous processes that determine the ﬁdelity of
DNA replication in human cells. Several of these involve the
accurate and processive behavior of the replicative DNA
polymerases d and e which perform DNA synthesis of the six
billion nucleotides that constitute the human genome. The past
several years have seen dramatic progress in our understanding
of the world of eukaryotic DNA polymerases. Human cells are* Corresponding authors. Fax: +33-5-61-17-59-94 (J.-S. Hoﬀmann).
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dependent DNA polymerases [1], which could be categorized
into two distinct families on the basis of their inﬁdelity in
replicating DNA. Emerging information suggests that con-
nections between DNA polymerase function or expression and
cancer may occur [2]. This may be the case for the mis-
regulation of DNA polymerase b (Pol bÞ; one of the struc-
turally simplest of the known mammalian DNA polymerases,
which is believed to function primarily in the repair of dam-
aged bases in normal somatic cells [3]. It is a monomeric
protein of 335 amino acids (39 kDa) that lacks exonuclease
activities, resulting in inaccuracy of DNA synthesis [4]. In a
normal cellular context, Pol b is expressed at a constant low
level and its role is believed to be restricted to repair synthesis
in the base exision repair (BER) and single strand break repair
(SSBR) pathways participating in maintenance of genome
stability [5]. The highly coordinated nature of these repair
pathways suggests that both loss and overexpression of genes
involved in these mechanisms may aﬀect their overall eﬃ-
ciencies. Indeed, this is the case for Pol b: treatment of Pol b
null mouse embryonic ﬁbroblasts with DNA alkylating and
oxidizing agents leads to increased cytotoxicity, gene muta-
tions and chromosomal aberrations when compared to iso-
genic wild-type (WT) cell lines [3,6]; conversely, by using
transfected mammalian cells and an overexpression vector, we
have demonstrated that only a 2-fold overexpression of ectopic
Pol b as compared to the endogenous Pol b resulted in an el-
evated mutation rate, chromosome instability, and accelerated
tumorigenesis [7,8]. Excess of Pol b has been found in some
human tumors: at the RNA level, Pol b is overexpressed in
many cancer cells [9]; high levels of Pol b have also been de-
tected at the protein level in ovarian tumors [10] as well as
prostate, breast or colon cancer tissues, compared to adjacent
normal tissues [11]; furthermore, Pol b level and activity are
increased in chronic myelogenous leukemia patients (unpub-
lished data) and melanomas [12]. Using cellular and molecular
models, we previously demonstrated that excess Pol b can
substitute for the replicative DNA polymerases during error-
free DNA transactions such as repair [10], replication [13], or
recombination (submitted data) pathways and can renderblished by Elsevier B.V. All rights reserved.
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propose that a rigorous regulation of the error-prone DNA
polymerases is essential for normal cell survival and that their
overexpression may be relevant only in cancer cells. In order to
address these questions, we report here the generation of mice
overexpressing transgenes (Tgs) bearing the Pol b Sh-ble
cDNA/Sh-ble cDNA fusion genes under the control of two
ubiquitously active regulatory sequences, the promoter of the
Cytomegalovirus (CMV) [14] that is active during develop-
ment, and the promoter of the mouse H-2K gene (H-2K) from
the major histocompatibility complex, which drives expression
after birth [15].2. Materials and methods
2.1. Construction of Tg expression vectors
The transgenic vectors were prepared on a pCDNA II backbone
(Invitrogen), at the unique KpnI site with a fragment containing the H-
2K promoter, the b globin intron, and the b globin poly(A) sequence
signal, to give plasmid pC-H-2K. The cDNA of rat Pol b, fused in
frame with the bacterial gene conferring resistance to zeocin [16], was
PCR-ampliﬁed from the pUTPolb plasmid using the primers
CCCTGCGCATGGCACTCGTGGAA and TTTAGCGCTCAGT-
CCTGCTCCTCGGCCA to create a Eco47III–FspI fragment that was
inserted into the pC-H-2K plasmid, opened with BamHI and then
treated with Klenow fragment polymerase. The KpnI fragment was
used as Tg for the microinjections of one-cell stage mouse embryos
(Fig. 1).
2.2. Generation of transgenic mice
The 3.8 Kb-long CMV and the 5.2 Kb-long KpnI (H-2K) fragments
containing the Pol b cDNA Tgs were micro-injected into fertilized
(CBAC57Bl/6) (CBAC57Bl/6) oocytes to obtain Tg founders,
which were crossed with (CBAC57Bl/6) WT mice and then back-
crossed to WT mice or intercrossed to derive Tg lines.
2.3. Southern blot
Genomic DNA was digested by EcoRV and products were electro-
phoretically separated in a 0.8 % agarose gel. DNA present in the gel
was depurinated in HCl 0.25 N solution and denaturated in 0.4 N
NaOH solution before being transferred on nylon HYBOND N+
membrane. Membrane was prehybridized overnight at 42 C in Hy-
brisol solution (Oncor) and hybridized in the same buﬀer with 32P
labelled Zeo (Sh) probe overnight at 42 C. The membrane was washed
twice with SSPE 2, 0.1 % SDS for 15 min at room temperature and
once with SSPE 0.1/SDS, 0.1 % for 15 min. Detection was achieved
by autoradiography.
2.4. PCRs
PCR was achieved on tail genomic DNA using primers speciﬁc for
the Sh sequence (Zeo 50: GCCAAGTTGACCAGTGCCGTT; Zeo 30:
CGGAAGTTCGTGGACACGACCT).β-glob Poly(A)Pol β cDNA::Shβ-globin Intron
CMV promotor
CMV/Pol β Transgene (3.8 Kb)
Kpn I Kpn I
Zeo Probe
β-glob Poly(A)Pol β cDNA::Shβ-globin IntronH-2K promotor
H-2K/Pol β Transgene (5.2 Kb)
Kpn I Kpn I
Zeo Probe
Fig. 1. Diagram of the CMV-Pol b::Sh and the H-2K-Pol b::Sh Tgs.
The transgenic vectors were prepared as indicated in Section 2. The
KpnI fragments were used as Tgs for the microinjections of one-cell
stage mouse embryos.2.5. RT-PCRs
Total RNA preparation: 30 mg of freshly excised tissue was ground
in RLT buﬀer in the presence of resin using a pestle adapted for Ep-
pendorf tubes (Geno Technology). After centrifugation, RNA ex-
traction was performed with Rneasy Protect kit (Qiagen). Quality of
RNA was conﬁrmed by analysis with Agilent Technologies 2100
Bioanalyzer – Bio Sizing (Version A.02.05 S1243). Reverse transcrip-
tion and PCR (RT-PCR) were processed in one tube using the Access
RT-PCR kit (Promega). One microgram of total RNA was reverse
transcribed and the PCR ampliﬁcation was achieved with the speciﬁc
Zeo 50 and Zeo 30 primers.
2.6. Northern blot
Total RNA was prepared as described above. For the Northern blot
analysis, 30 lg of total RNA was denatured 10 min at 65 C in de-
naturation buﬀer. RNA samples were electrophoretically fractionated
in a 2% gel containing MOPS 1 and formaldehyde 0.5 and blotted
to a N+ membrane in SSC 10 buﬀer. Membrane was prehybridized
overnight at 42 C in Hybrisol solution (Oncor) and hybridized in the
same buﬀer with 32P labelled Zeo probe overnight at 42 C. The
membrane was washed once with SSC 0.5 for 15 min. at room
temperature and twice with SSC 0.1/SDS 0.1% for 15 min at 55 C.
Detection was achieved by phosphoImager storm system analysis
(Molecular Dynamics).
2.7. Western blotting
Organs were disrupted and lysed in SDS-containing buﬀer according
to the protocol described previously [11]. For analysis of Pol b, 100 lg
of organ protein was electrophoresed in a 12% SDS–PAGE gel and
transferred to PVDF membrane (Appligen). Blots were blocked in
TBS-T (0.1% Tween) with 5% skimmed milk and incubated with Pol b
polyclonal antibody (1/5000) (provided by Dr. Sam Wilson, NIEHS,
NC) followed by incubation with horseradish peroxidase conjugated
anti rabbit IgG, and revealed using the ECL system (Amersham).
Equal loading was determined using monoclonal antibody to actin (1/
5000) (Chemicon, Euromedex, France). Quantiﬁcation was made by
PhosphoImager Storm-system analysis (Molecular Dynamics) using
Imagequant software.
2.8. Macroscopic examination of the mice
Mice were housed in a room lighted from 7 a.m. to 7 p.m., kept at a
temperature of 19–21 C with a relative humidity of 60 15%. Food
and sterile water were provided ad libitum. The mice were housed 5 per
cage and kept until natural death. Animal care consisted of weekly
cleaning of the cages and bottles, changing sawdust litter (pine, heat
treated), daily monitoring of the animals and the use of germ-limited
conditions by the keeper (gloves, gown, covered hair). Body weights
were recorded monthly. This study was performed in compliance with
FELASA recommendations. An animal care committee approved the
experiment.
Some of the animals were excluded from the necropsy study when
postmortem decomposition was too severe. Thus, the necropsy was
performed on 23 mice (16 Polb mice and 7 control mice). Macroscopic
examination was systematically performed. The following organs were
removed: lungs, heart, thymus, liver, spleen, pancreas, intestinal tract,
lymph nodes, kidneys, adrenal glands, ovaries, uterus, testis, bone
marrow, salivary glands, and brain. Some tissue samples were frozen
for further analysis (see below) and the remaining tissues were ﬁxed in
formalin. After paraﬃn embedding, 5-lm thick sections were prepared
and the slides stained with hematoxylin–eosin.3. Results and discussion
The design of the CMV-Pol b::Sh Tg and H-2K-Pol b::Sh Tg
(Fig. 1) was based on three main considerations: (a) the Pol b-
Sh cDNA was placed under the control of either the CMV
promoter or that of the murine MHC class I H-2K gene to
drive Tg expression in a wide variety of tissues, as shown for
other reporters; indeed, when CMV [14] or when 2 Kb of the
H-2K upstream regulatory sequences were fused to several
reporter genes, such as hGH [15], c-myc [17], or v-jun [18],
fusion genes were ubiquitously expressed in adult organs of
Fig. 3. Analysis of the expression of the Tg mRNA by Northern blot in
various tissues of control and the 8a transgenic mice. RNA prepara-
tion and Northern blot analysis were performed as indicated in Section
2. C, Control experiment using the CHO::Pol b cell line transfected by
the pUTPolb plasmid, overexpressing Pol b by 4-fold [8].
Fig. 4. Immunoblotting analysis of Pol b level in thymus from control
and the 8a Tg mice. Expression of Pol b in the thymus of Control (C)
and Tg8a lines was analyzed by using Pol b polyclonal antibodies that
were provided by Dr. S. Wilson, NIEHS, NC, USA. a-Actin served as
a loading control.
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resistance to the broad-spectrum zeocin antibiotic of the
phleomycin family, was fused in frame with the NH2 terminus
of the Pol b protein to discriminate between Tg and endoge-
nous Pol b expression; and (c) the Pol b-Sh cDNA was linked
to the b-globin intron and polyadenylation site to enhance
transcription and stabilize mRNA, respectively. Only one
CMV Tg line and ﬁve independent H-2K Tg lines, named 1,
3a, 3b, 8a, and 8b were derived (Fig. 2A), which have distinct
Tg integration patterns as demonstrated by Southern blot
analysis (Fig. 2B). The line 3b was eliminated since it was
sterile.
For all lines, the heterozygous mice developed to maturity
with no obvious abnormalities. These heterozygotes were then
bred to homozygosity to increase the potential eﬀect of the
deregulated polymerase. Mice homozygous for the Pol b
overexpression were obtained at the expected Mendelian fre-
quency. When intercrossed, their oﬀspring were viable and
fertile. We ﬁrst analyzed the Tg mRNA expression by
Northern blot in diﬀerent adult tissues of each Tg line. Ex-
pression of Tg was also investigated by Western blot analysis
using a polyclonal anti-Pol b antibody. No expression of the
CMV Tg was observed, strongly suggesting a deleterious eﬀect
of Pol b overexpression during development. In contrast, we
observed expression of the Tg when driven by the H-2K pro-
moter in one of the 5 lines, the 8a line, whereas the lines 1, 3a
and 8b did not express the Tg. Using a Tg speciﬁc probe (Sh),
expression of the Tg in the 8a line was observed at the mRNA
level exclusively limited to the thymus (Fig. 3). This observa-
tion was conﬁrmed with the protein expression analysis by
Western blot (Fig. 4), which indicates that the level of Tg ex-
pression is several fold above the level of endogenous Pol b.
These ﬁndings show that, despite a strong promoter, most of
the organs do not tolerate high level of the ectopic Pol b,
supporting that tight regulation of Pol b occurs in these or-
gans. Since we could not observe Tg expression at RNA andFig. 2. Generation of transgenic mice. (A) Transgenic founders were
identiﬁed by PCR on tail genomic DNA using primers speciﬁc for the
Sh sequence; C: non-transgenic control littermates; Tg: Transgenic
animals; P: positive control PCR using the vector bearing the Tg as
DNA template. (B) Analysis of the integration of the H-2k/Pol b
construct by Southern blot in the Tg lines 1, 3a, 3b, 8a, and 8b. The
arrows represent the 30 ﬂanking sequences.protein level in organs other than thymus, we could speculate
that Pol b overexpression is down regulated by transcriptional
control or RNA degradation. The thymus is a highly replica-
tive organ where all the replicative and repair machineries are
activated; furthermore, the mutagenic impact of high level of
Pol b is thwarted in this organ by excess mismatch repair
proteins which can eliminate mismatches introduced into
DNA by the up-regulated Pol b.
In order to examine the survival of H-2K/Pol b 8a animals
that overexpressed Pol b, we maintained 300 WT, 300 het-
erozygotes, and 69 homozygous animals in identical conditions
and recorded the time when they became moribund or the time
of natural death. None of the three classes of mice died during
the ﬁrst 6 months of life. Between 6 and 9 months after birth
(mean 7-month-old), twenty ﬁve (36%) of the homozygous
animals died prematurely quite suddenly without any pre-
mortem symptoms, equally among males and females. Such a
mortality was never observed for WT and heterozygous ani-
mals. These results suggest that Tg Pol b expression in thymus
or in other organs even if undetected (less than 2-fold over-
expression) could be responsible for shortened life span. Be-
cause Pol b is the major BER polymerase, a tightly
coordinated mechanism for repair of DNA base damage via
alkylation and oxidation as well as base losses, imbalance of its
expression may cause an overall functional deﬁciency of the
elimination of the numerous endogenous oxidative DNA
damage events that have accumulated during the ﬁrst months
of life of the mice. This could explain the deleterious impact of
excess Pol b in vivo that we observed in this study. Moreover,
we found that homozygous Tg mice showed a distinctive
phenotype with thinness and frequent spastic crisis resembling
epilepsy. At 6 months of age, homozygous female mice
weighed between 20 and 30 g (mean at 24–25 g) and homo-
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less than 6-month-old-WT or heterozygous animals (average
at 30 g for the females and 35 g for the males) (P < 0:01).
We then performed systematically macroscopic examination
of 46 mice (23 homozygous animals alive at 6–9 months; 16
prematurely dead homozygous mice and 7 control mice). The
following organs were removed: lungs, heart, thymus, liver,
spleen, pancreas, intestinal tract, lymph nodes, kidneys, adre-
nal glands, ovaries, uterus, testis, bone marrow, salivary
glands, and brain. When analysis was performed randomly on
14 homozygous animals alive at 6–9 months, enlarged thymus
was observed. On the prematurely dead transgenic animals, we
found no obvious abnormality that could explain the mortal-
ity. Liver and pancreas were histologically normal, brain
structure and histology were not modiﬁed. There was no sig-
niﬁcant diﬀerence between Tg mice and controls in terms of
neuronal and astrocytic cellularity as revealed by the GFAP
immunostainings (not shown). The heart, lungs, kidneys, and
intestinal tract were normal. Lymphoid organs such as thymus
and spleen were histologically normal. Furthermore, macro-
scopic and microscopic analysis did not reveal any tumoral
lesion. This indicates that the unique event, overexpression of
Pol b, is not suﬃcient to induce tumorigenesis in vivo. Muta-
genesis, chromosome instability and tumorigenesis impacts of
Pol b overexpression have been previously described ex vivo in
CHO cells [7,8] where ectopic expression of Pol b induces high
frequency of spontaneous mutations, aneuploidy, an abnormal
localization of the centrosome-associated c-tubulin protein
during mitosis, a deﬁcient mitotic checkpoint, and promotes
tumorigenesis in nude immunodeﬁcient mice. Thus, it was
proposed that alteration of Pol b expression in CHO cells
appears to induce major genetic changes associated with a
malignant phenotype. Some of the molecular bases leading to
these genetic instabilities were analyzed and it was found that
excess Pol b could compete with the accurate DNA polyme-
rases during DNA transactions such as DNA replication [13]
or DNA repair [10], resulting in highly error-prone DNA
synthesis. However, the CHO/AA8 cell line used in these su-
dies was a derivative from the CHO-K1 cell line which has amutant p53 sequence. Preliminary attempts to overexpress Pol
b in a normal p53 background CHO were unsuccessful (un-
published data). Thus, it is possible that tolerance of high level
of Pol b in murine cells may require another oncogenic event.
Our in vivo data presented here support this hypothesis.
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